<DOC>
	<DOCNO>NCT00439400</DOCNO>
	<brief_summary>The objective study assess safety efficacy doxycycline 0.025 % ( ALTY-0501 ) ophthalmic solution treatment dry eye use Controlled Adverse Environment ( CAE ) Model .</brief_summary>
	<brief_title>A Study ALTY-0501 Treatment Dry Eye Administered 4 Times Day 56 Day Period</brief_title>
	<detailed_description>Dry eye prevalent form ocular discomfort irritation . Estimates range 20 million people US affect mild dry eye , literature report many 3.2 million American woman suffer clinically significant dry eye . ( Schaumberg et al , 2003 ) . Dry eye related external factor , low humidity air condition office , winter heating , dusty windy outdoor environment , prolong use computer , wear contact lens , well internal factor , hormonal imbalance , autoimmune disease , presence many widely prescribed systemic medication , anatomical change trauma , age . Chronic dry eye disease associate immune-based inflammation lacrimal gland ocular surface . Symptoms result mildly decrease quality life minimum , increase severity , loss function productivity , pain , light sensitivity , misery accompanies significantly impaired vision decrease quality life . With age population United States country develop world , increase computer use , dry eye become prevalent . Doxycycline well establish anti-infective drug , use systemically ophthalmologists treat moderate severe case blepharitis year . Recently demonstrate doxycycline low , non-antimicrobial concentration also powerful anti-proteolytic anti-inflammatory property . Anecdotal report use 0.025 % doxycyline eyedrops human patient dry eye and/or meibomian gland disease indicate significant improvement ocular surface stain significant decrease patient symptom .</detailed_description>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>Are 18 year age old ; Are able willing follow instruction , include participation study assessment , present require study visit duration study ; Have diagnosis dry eye associate meibomian gland disease ; A fluorescein stain stain score ≥ 1+ least one region cornea ; Presence eyelid telangiectasia and/or inspissation metaplasia meibomian gland orifice ; An ocular dryness score ≥1+ ; Have TFBUT ≤ 7 second least one eye Visit 1 ; Have best correct visual acuity ( BCVA ) +0.7 good assess Early Treatment Diabetic Retinopathy Study ( ETDRS ) scale eye Visit 1 ; ( If female childbearing potential ) Are pregnant , nursing , plan pregnancy . Women childbearing potential require negative urine pregnancy test screen exit visit agree use acceptable method contraception duration study ; Have anterior blepharitis , deem clinically significant and/or likely interfere study parameter opinion investigator ; Are diagnose ongoing ocular infection ( bacterial , viral , fungal ) , active ocular inflammation ( e.g. , follicular conjunctivitis ) ; Report ocular discomfort score 4 eye time 0 CAE exposure Visit 2 ; Wear contact lenses within 1 week Visit 1 throughout course study ; Have contact lensinduced dry eye ; Have previously laser situ keratomileusis ( LASIK ) surgery ; Are currently take topical ophthalmic prescription overthecounter ( OTC ) solution , artificial tear , gel scrub discontinue medication duration trial ; Have use Restasis® within 30 day Visit 1 ; Have use eye drop within 2 hour Visit 1 ; Any eye drop contain BAK preservative 1 week prior study start ; Have systemic disease , uncontrolled medical condition , opinion investigator could interfere study measurement subject compliance ; Are currently take ( Visit 1 ) medication know cause ocular drying use stable dose regimen 30 day prior Visit 1 ; Are currently pregnant , nursing , plan pregnancy ; ( For woman childbearing potential ) Be unwilling submit urine sample pregnancy test Visit 1 exit visit ; Have receive another experimental drug device within 30 day visit 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>